Genialis

From Friday runs to finish lines 💪 After 6 months of training, our team conquered the 5k, 10k, and half marathon in Slovenske Konjice—with a 7kg chocolate boost at the end 🤗

It's true, there are many targeted treatment options for NSCLC, with even more in active clinical development. ❓But how many patients 𝗮𝗰𝘁𝘂𝗮𝗹𝗹𝘆 𝘂𝗻𝗱𝗲𝗿𝗴𝗼 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 to ensure they receive the most effective therapies? In collaboration with University Clinic Golnik, we’re presenting a poster at #ENA24, where we analyzed testing rates and observed frequencies of key molecular alterations 🧬 (EGFR, KRAS, BRAF, ALK, ROS1) and PD-L1 expression in 1,600 patients. (This represents around 40% of all NSCLC cases diagnosed in Slovenia, including early-stage cases that are rarely reported globally.) Our findings? Over 𝟵𝟱% of late-stage patients with identified biomarkers received targeted therapy in early lines of treatment. Biomarker testing, in both early and late-stage NSCLC, is essential to providing patients with the most suitable therapies. 💡 Learn more from our poster (https://lnkd.in/d67WPS7S) or catch it live in Barcelona! ✍ Katja Mohorčič, Roman Luštrik, Žan Kuralt, Mark Uhlik, Izidor Kern, Luka Ausec

⚕️ 💻 What are some of the ways we in the AI for Drug Discovery and Development can contribute to better patient outcomes, especially for under-represented patient groups? 🏥 🌍 That was the over-arching question I tried to address in a recent interview with Authority Magazine. We spoke about acknowledging and filling data gaps, building trust with empathy and the difference between a system for healthcare and sick care, among many other topics. Please have a read and leave a comment below to join the conversation. https://lnkd.in/gz2iwym5 These are important conversations to have, so if you'd like to get more involved in this problem space, please follow Genialis and The Alliance for Artificial Intelligence in Healthcare (AAIH). I would also whole-heartedly recommend the leadership of the Digital Medicine Society (DiMe) and Jennifer Goldsack. H/t to Ricky Mehra for opening my eyes to the health v sick care distinction. Thanks for the soapbox, Authority Magazine Interview-Series !!

“I think it’s fair to say that QIAGEN literally democratized access to molecular biology for thousands of labs all over the world. It started more than 40 years ago. And we need to remember, if we close our eyes, that there is probably a before and after QIAGEN in molecular techniques.” If you hadn't had the chance to listen to the latest episode of Talking Precision Medicine featuring Thierry BERNARD, tune in here: https://lnkd.in/dpG2pwsQ

📸: Miha Stajdohar presenting how the Xerna TME Panel earned the confidence of drug developers and regulators at #XAIB24. This afternoon, catch him in a panel discussion on responsible AI with  Richard Milne (University of Cambridge), Stein Aerts (VIB), and Philip Kim (Fable Therapeutics).

📸: Genialis' Joshua Wheeler, MD, PhD, presenting at the PanCAN Scientific Summit 2024 Meet the rest of our team this fall at: 🟡 Explainable AI in Biology Conference 2024 | October 15-18, 2024 | Cambridge, United Kingdom | The BioDev Network 🟡 HLTH 2024 | October 20-23 | Las Vegas, NV | HLTH USA 🟡 ENA 24 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics | October 23-25, 2024 | Barcelona, Spain | EORTC - European Organisation for Research and Treatment of Cancer, National Cancer Institute (NCI), American Association for Cancer Research 🟡 SITC 39th Annual Meeting & Pre-Conference Programs | November 6-11 | Houston, TX | Society for Immunotherapy of Cancer (SITC) See you there!

What would you say is the ratio of breakthroughs to breakdowns in AI drug development? ⚖️ Yesterday at BioTechX Europe, our CTO, Miha Stajdohar, tackled this question in a panel. Thank you, Blanca Baez (DBounce Ltd), James Zanewicz, JD, LLM, RTTP (Tulane University School of Medicine), Bruce Press (ZS), and Martin Akerman (Envisagenics) for a lively discussion! In case you missed it, you still have a chance to catch Miha in action today. 💡"Foundation Models for RNA Biomarkers" 🕛 12:45 PM 📍 Theatre 3 - AI in Drug Development and Discovery Hope to see you there! #BioTechX The Alliance for Artificial Intelligence in Healthcare (AAIH)

“You might be surprised to learn that I'm not a scientist by background. However, something like 25 years ago, I literally fell in love with diagnostics and its complexity.” In the latest episode of the Talking Precision Medicine podcast, we had the pleasure of hosting Thierry BERNARD, CEO of QIAGEN, world’s key player in molecular diagnostics. 🌍 Find the full episode here: https://lnkd.in/dpG2pwsQ Joined by Genialis' CEO, Rafael Rosengarten, they explore: 🔹Breaking new ground in precision medicine with novel diagnostic technologies 🔹Overcoming global regulatory hurdles  🔹The future of diagnostics in non-oncology fields like neurodegenerative diseases 🔹Harnessing AI to transform data into actionable clinical insights

We have life-saving targeted therapies But all too often, we have a hard time predicting whether a cancer patient will respond to them ⚠️ Genialis™ krasID uses biology-informed machine learning to change that Our poster at the Annual RAS-Targeted Drug Development Summit revealed that krasID can: ➡️ Predict G12C KRASi sensitivity in real-world NSCLC patients  ➡️ Identify potential immune checkpoint inhibitor combination responders ➡️ Pinpoint actionable biologies in relapse settings It’s a step closer to personalized treatments for cancer patients who need it most See the poster here: https://lnkd.in/ghG_P-f6

How do we turn high-tech innovations into real-world healthcare solutions? Rafael Rosengarten, our CEO, led a panel on this very topic at the AI in Health Conference (Rice Ken Kennedy Institute). 💡 Catch the full discussion - featuring insights from Jim Colson (Texas A&M Health Science Center), Ginny Torno (Houston Methodist), and Andrea Vuturo (Vuturo Group) - here: https://lnkd.in/daawWZhN